This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look at Adagrasib (MRTX849) as a therapy for KRASG12C-mutated NSCLC
Ticker(s): MRTXWho's the expert?
Institution: Private Practice
- 12 years of academic practice specializing in medical oncology.
- treats 18 patients with unresectable hepatocellular carcinoma
- familiar with both the HIMALAYA Phase III trial and the STRIDE regimen
Interview GoalDiscuss the practice-informing adverse event patterns and management in the KRYSTAL-1 Phase 2 study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC. The ESMO poster presentation on the Clinical Efficacy of adagrasib(MRTX849) in Patients with Previously Treated KRASG12C-Mutated Advanced NSCLC
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
